ArticleNeurobiology of disease2021
Tau associated peripheral and central neurodegeneration: Identification of an early imaging marker for tauopathy.
Article in Neurobiology of disease, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 27 citations in OpenAlex.
- Selective inhibition of monoamine oxidase B represents a therapeutic strategy for diabetic peripheral neuropathy.Acta pharmacologica Sinica · 2026Article
- Peripheral immunochemical considerations in Parkinson disease: sources, targets and crosstalk mechanisms.Journal of translational medicine · 2026Review
- Superior Laryngeal Nerve Function in an Alzheimer's Disease Rat Model: A Pilot Study.The Laryngoscope · 2026Article
- Combined serum neurofilament light chain and Tau as biomarkers of diabetic peripheral neuropathy.Frontiers in endocrinology · 2026Article
- Differential effects of age and sex on tau pathology propagation in the htau mouse model: A neuropathological and proteomic study.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Glabridin as a selective Kv2.1 inhibitor ameliorates DPN pathology by disrupting the Aβ/Kv2.1/JNK/NF-κB/NLRP3/p-Tau pathway.Acta pharmacologica Sinica · 2025Article
- Peripheral proteinopathy in neurodegenerative diseases.Translational neurodegeneration · 2025Review
- Validation of a functional human AD model with four AD therapeutics utilizing patterned ipsc-derived cortical neurons integrated with microelectrode arrays.Scientific reports · 2024Article
- Long COVID could become a widespread post-pandemic disease? A debate on the organs most affected.Naunyn-Schmiedeberg's archives of pharmacology · 2023Review
- In-vivo corneal confocal microscopy: Imaging analysis, biological insights and future directions.Communications biology · 2023Review
- Role of Tau protein in long COVID and potential therapeutic targets.Frontiers in cellular and infection microbiology · 2023Review
- Using Corneal Confocal Microscopy to Identify Therapeutic Agents for Diabetic Neuropathy.Journal of clinical medicine · 2022Article
- Loss of corneal nerves and brain volume in mild cognitive impairment and dementia.Alzheimer's & dementia (New York, N. Y.) · 2022Article
- Elongator promotes neuritogenesisFrontiers in cell and developmental biology · 2022Article
- The Cellular Senescence Stress Response in Post-Mitotic Brain Cells: Cell Survival at the Expense of Tissue Degeneration.Life (Basel, Switzerland) · 2021Review
- Corneal Confocal Microscopy to Image Small Nerve Fiber Degeneration: Ophthalmology Meets Neurology.Frontiers in pain research (Lausanne, Switzerland) · 2021Review
- Association between plasma p-tau181 levels and the evolution of cognitive and physical performance in a cohort of cognitively impaired older adults with frailty criteria: Longitudinal data from the CogFrail study.Alzheimer's & dementia (New York, N. Y.)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 6 institutions in 3 countries.
Funding
Abstract
Pathological hyperphosphorylated tau is a key feature of Alzheimer's disease (AD) and Frontotemporal dementia (FTD). Using transgenic mice overexpressing human non-mutated tau (htau mice), we assessed the contribution of tau to peripheral and central neurodegeneration. Indices of peripheral small and large fiber neuropathy and learning and memory performances were assessed at 3 and 6 months of age. Overexpression of human tau is associated with peripheral neuropathy at 6 months of age. Our study also provides evidence that non-mutated tau hyperphosphorylation plays a critical role in memory deficits. In addition, htau mice had reduced stromal corneal nerve length with preservation of sub-basal corneal nerves, consistent with a somatofugal degeneration. Corneal nerve degeneration occurred prior to any cognitive deficits and peripheral neuropathy. Stromal corneal nerve loss was observed in patients with FTD but not AD. Corneal confocal microscopy may be used to identify early neurodegeneration and differentiate FTD from AD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.